{"id":"brinzolamide-brimonidine-fc","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular hyperemia"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Ocular discomfort"},{"rate":null,"effect":"Taste perversion"},{"rate":null,"effect":"Allergic conjunctivitis"}]},"_chembl":{"chemblId":"CHEMBL2062257","moleculeType":"Small molecule","molecularWeight":"442.23"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Brinzolamide decreases aqueous humor production by inhibiting carbonic anhydrase in the ciliary body. Brimonidine is an alpha-2 adrenergic agonist that both reduces aqueous humor production and increases uveoscleral outflow. Together, these complementary mechanisms provide additive IOP-lowering effects.","oneSentence":"This fixed combination reduces intraocular pressure by inhibiting carbonic anhydrase (brinzolamide) and activating alpha-2 adrenergic receptors (brimonidine).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:21:39.186Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT03192826","phase":"PHASE4","title":"Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy","status":"COMPLETED","sponsor":"University Hospital of Patras","startDate":"2016-06-20","conditions":"Posterior Capsule Opacification, Ocular Hypertension","enrollment":79},{"nctId":"NCT01309204","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID Plus Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":1184},{"nctId":"NCT01310777","phase":"PHASE3","title":"Brinzolamide/Brimonidine Twice a Day (BID) Fixed Combination (FC) vs Brinzolamide BID and Brimonidine BID in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-05","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":771}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SIMBRINZA (brinzolamide/brimonidine 1%/0.2%), Alcon Lab. Ltd"],"phase":"marketed","status":"active","brandName":"Brinzolamide/Brimonidine FC","genericName":"Brinzolamide/Brimonidine FC","companyName":"University Hospital of Patras","companyId":"university-hospital-of-patras","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This fixed combination reduces intraocular pressure by inhibiting carbonic anhydrase (brinzolamide) and activating alpha-2 adrenergic receptors (brimonidine). Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}